Puma Biotechnology Inc. (PBYI)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that inducement awards were granted to staff hired in March, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).

Puma SE is poised for a turnaround with strong growth plans in the US market and strategic athlete endorsements, leading me to assign a "Buy" recommendation. Despite recent subpar financial performanc...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will present clinical data on its drug neratinib in a poster presentation on April 28 at the 2025 AACR Annual Meeting.

Puma SE's stock has dropped nearly 50% year-to-date, with an additional 20% decline following its Q4 earnings, creating a potential value opportunity for long-term investors. Despite consistent revenu...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will prov...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

Puma Biotechnology beats on fourth-quarter 2024 earnings and sales. The company issues a fresh financial guidance for 2025.

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director-Investor Relations Alan Auerbach – Presid...

Puma Biotech (PBYI) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.31 per share a year ago.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 4Q and FY-2024 earnings results after the close on Feb. 27 and follow with a conference call to discuss results.